GBIO GENERATION BIO CO revenue, earnings and financials
For the quarter ended September 30, 2025, GENERATION BIO CO reported revenue of $1.59M (down 78.9% from a year earlier), net income of −$5.52M and diluted EPS of −$0.82; over the last four quarters revenue was $15.3M and net income −$62.6M; for the fiscal year ended December 2024 revenue was $19.9M, up 236.9% on the year before.
GBIO annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $19.9M, gross profit n/a, operating income −$142M, net income −$132M (margin -661.9%), EPS −$1.98
- Fiscal year ended Dec 2023: revenue $5.90M, gross profit n/a, operating income −$139M, net income −$127M (margin -2144.5%), EPS −$1.96
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$141M, net income −$137M (margin n/a), EPS −$2.35
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$119M, net income −$119M (margin n/a), EPS −$2.12
GBIO quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue $1.59M (down 78.9% year over year), net income −$5.52M, EPS −$0.82
- Quarter ended Jun 30, 2025: revenue $765K (down 81.3% year over year), net income −$20.9M, EPS −$3.12
- Quarter ended Mar 31, 2025: revenue $8.72M (up 114.9% year over year), net income −$14.8M, EPS −$0.22
- Quarter ended Dec 31, 2024 (from the annual report): revenue $4.19M (up 45.5% year over year), net income −$21.4M, EPS $4.50
- Quarter ended Sep 30, 2024: revenue $7.55M (up 252.0% year over year), net income −$15.3M, EPS −$2.29
- Quarter ended Jun 30, 2024: revenue $4.09M (up 364.9% year over year), net income −$20.4M, EPS −$3.07
- Quarter ended Mar 31, 2024: revenue $4.06M, net income −$74.5M, EPS −$1.12
- Quarter ended Dec 31, 2023 (from the annual report): revenue $2.88M, net income −$35.2M, EPS −$0.53
- Quarter ended Sep 30, 2023: revenue $2.15M, net income −$28.3M, EPS −$0.43
- Quarter ended Jun 30, 2023: revenue $880K, net income −$31.1M, EPS −$0.47
- Quarter ended Mar 31, 2023: revenue $0, net income −$32.1M, EPS −$0.53
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$32.4M, EPS −$0.55
- Quarter ended Sep 30, 2022: revenue $0, net income −$31.3M, EPS −$0.53
- Quarter ended Jun 30, 2022: revenue $0, net income −$37.9M, EPS −$0.66
- Quarter ended Mar 31, 2022: revenue n/a, net income −$35.0M, EPS −$0.61
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$30.9M, EPS −$0.55
- Quarter ended Sep 30, 2021: revenue n/a, net income −$31.9M, EPS −$0.56
- Quarter ended Jun 30, 2021: revenue n/a, net income −$30.8M, EPS −$0.55
- Quarter ended Mar 31, 2021: revenue n/a, net income −$25.6M, EPS −$0.46
GBIO cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$88.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$52.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$102M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$91.8M, share buybacks n/a
GBIO balance sheet
- Sep 30, 2025: cash $21.9M, total assets $122M, total liabilities $71.3M, shareholders' equity $50.6M
- Jun 30, 2025: cash $49.1M, total assets $179M, total liabilities $125M, shareholders' equity $54.1M
- Mar 31, 2025: cash $50.9M, total assets $201M, total liabilities $128M, shareholders' equity $73.3M
- Dec 31, 2024: cash $76.3M, total assets $231M, total liabilities $145M, shareholders' equity $86.2M
- Sep 30, 2024: cash $21.7M, total assets $249M, total liabilities $144M, shareholders' equity $104M
- Jun 30, 2024: cash $28.5M, total assets $265M, total liabilities $150M, shareholders' equity $115M
- Mar 31, 2024: cash $35.5M, total assets $286M, total liabilities $154M, shareholders' equity $132M
- Dec 31, 2023: cash $66.4M, total assets $375M, total liabilities $172M, shareholders' equity $203M
What is GBIO's revenue?
GENERATION BIO CO reported $15.3M of revenue over its last four quarters, through September 30, 2025.
Is GBIO profitable?
No. GENERATION BIO CO lost $62.6M over the last four quarters.
What is GBIO's EPS?
Diluted earnings per share over the last four quarters were $0.34; −$0.82 in the latest quarter.